Anti B cell targeted immunotherapy for treatment of refractory autoimmune haemolytic anaemia in a young infant

Archives of Disease in Childhood

Volumn 88, Issue 4, 2003, Pages 337-339

  Ng, P C ^a   Lee, K K M ^a   Lo, A F C ^a   Li, C K ^a   Fok, T F ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; METHYLPREDNISOLONE; NITRIC OXIDE; RITUXIMAB;

ACUTE KIDNEY FAILURE; ARTICLE; ARTIFICIAL VENTILATION; AUTOIMMUNE HEMOLYTIC ANEMIA; CASE REPORT; CAUSE OF DEATH; CLINICAL FEATURE; DRUG EFFICACY; DRUG USE; HEART FAILURE; HEMOLYSIS; HUMAN; IMMUNOTHERAPY; INFANT; MALE; MYCOSIS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; SYMPTOM; VIRUS PNEUMONIA;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; FATAL OUTCOME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; OPPORTUNISTIC INFECTIONS;

EID: 0037383363     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.88.4.337     Document Type: Article

References (16)

1. Letsky EA. Anaemia in the newborn. In: Roberton NRC, ed. Textbook of neonatology, 2nd edn. Churchill Livingstone, 1992:697-717.
2. Seeliger S, Baumann M, Mohr M, et al. Autologous peripheral blood stem cell transplantation and anti-B-cell directed immunotherapy for refractory auto-immune haemolytic anaemia. Eur J Pediatr 2001;160:492-6.
3. Ahrens N, Kingreen D, Seltsam A, et al. Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (Rituximab). Br J Haematol 2001;114:241-6.
4. Quartier P, Brethon B, Philippet P, et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001;358:1511-13.
5. Reff ME, Carner K, Chambers S, et al. Depletion of B-cells in vivo by a chimeric mouse monoclonal antibody to CD20. Blood 1994;83:435-45.
6. Onrust SV, Lamb HM, Balfour JA. Rituximab. Drug 1999;58:79-88.
7. Zaja F, Russo D, Fuga G, et al. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 2000;55:1062-3.
8. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology 1999;52:1701-4.
9. Perrotta S, Locatelli F, La Manna A, et al. Anti-CD20 monoclonal antibody (rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol 2002;116:465-7.
10. Saleh MN, Gutheil J, Moore M, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 2000;27:99-103.
11. Ratanatharathorn V, Carson E, Reynolds C, et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 2000;133:275-9.
12. Lee EJ, Kueck B. Rituxan in the treatment of cold agglutinin disease. Blood 1998;92:3490-1.
13. Bauduer F. Rituximab: a very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD-20 positive, low-grade non-Hodgkin's lymphoma. Br J Haematol 2001;112:1083-90.
14. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001;344:68-9.
15. Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 2000;96:1184-6.
16. Bermudez A, Marco F, Conde E, et al. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 2000;85:894-5.